MetaCap

NeOnc Technologies (NTHI) vs Retension Pharmaceuticals (RTSN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NeOnc Technologies is the larger company by market cap ($90.9 million vs $87.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NTHI+13.31%RTSN-0.19%
+81%+35%-11%
Oct 9, 20261 yearNov 20, 2026
NTHI+13.31%RTSN-0.19%
+81%+37%-7%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NTHI versus RTSN key metrics
MetricNTHIRTSN
Share price$3.15$10.51
Market cap$90.88M$87.57M
1-day change-9.48%-19.22%
YTD return-61.91%—
1-year return-46.25%—
EPS (TTM)$-1.95$-2.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$39.99K—
Revenue growth (YoY)-51.82%—
Net income (latest FY)$-62.15M—
Operating margin-145637.52%—
Net margin-155404.38%—
52-week high$11.38$18.64
52-week low$2.50$9.23
Distance from 52-week high-72.31%-43.62%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+439.68%+391.63%
Average volume187.23K144.93K
Shares outstanding28.85M8.33M
Employees512
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About NeOnc Technologies

NTHI stock →

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Retension Pharmaceuticals

RTSN stock →

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

NTHI vs RTSN FAQ

Which is bigger, NeOnc Technologies or Retension Pharmaceuticals?

NeOnc Technologies (NTHI) is larger, with a market capitalization of $90.88M compared with $87.57M for Retension Pharmaceuticals (RTSN).

Are NeOnc Technologies and Retension Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons